X T L Biopharmaceuticals reported $1.1M in Operating Expenses for its fiscal quarter ending in December of 2024.





Operating Expenses Change Date
Alaunos Therapeutics USD 1.19M 428K Sep/2025
Bioline Rx USD 2.63M 24K Sep/2025
Teva Pharmaceutical Industries USD 4.22B 812M Dec/2025
X T L Biopharmaceuticals USD 1.1M 175K Dec/2024